Study Type
Interventional - Drug
The objective of ARTESiA is to determine if treatment with apixaban, compared with aspirin, will reduce the risk of stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke.
Current guidelines recommend treatment with oral anticoagulant for stroke prevention in clinical atrial fibrillation (AF), but opinion leaders are uncertain of the role of oral anticoagulants for patients with SCAF.
A total of 4000 patients from approximately 240 sites in Canada, USA and Europe will be randomized double-blind to receive apixaban (5mg bid or 2.5 mg bid as per labelling) or aspirin (81mg OD).
The study will be event-driven and will continue until 248 patients have experienced a primary outcome event (stroke or systemic embolism). Estimated mean follow-up time is 3 years.
Along with Jeff Healey, the Co-Principal Investigators of ARTESIA are:
More about this study at: ARTESiA.
Rationale & Design - Download PDFInterventional - Drug
Multicentre, prospective, parallel group, double-blind design
16
230
4000
2015-2022
PHRI
Back To Top